Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase

L G Feun, A Marini, G Walker, G Elgart, F Moffat, S E Rodgers, C J Wu, M You, M Wangpaichitr, M T Kuo, W Sisson, A A Jungbluth, J Bomalaski, N Savaraj, L G Feun, A Marini, G Walker, G Elgart, F Moffat, S E Rodgers, C J Wu, M You, M Wangpaichitr, M T Kuo, W Sisson, A A Jungbluth, J Bomalaski, N Savaraj

Abstract

Background: Arginine-depleting therapy with pegylated arginine deiminase (ADI-PEG20) was reported to have activity in advanced melanoma in early phase I-II trial, and clinical trials are currently underway in other cancers. However, the optimal patient population who benefit from this treatment is unknown.

Methods: Advanced melanoma patients with accessible tumours had biopsy performed before the start of treatment with ADI-PEG20 and at the time of progression or relapse when amenable to determine whether argininosuccinate synthetase (ASS) expression in tumour was predictive of response to ADI-PEG20.

Results: Twenty-seven of thirty-eight patients treated had melanoma tumours assessable for ASS staining before treatment. Clinical benefit rate (CBR) and longer time to progression were associated with negative expression of tumour ASS. Only 1 of 10 patients with ASS-positive tumours (ASS+) had stable disease, whereas 4 of 17 (24%) had partial response and 5 had stable disease, when ASS expression was negative (ASS-), giving CBR rates of 52.9 vs 10%, P=0.041. Two responding patients with negative ASS expression before therapy had rebiopsy after tumour progression and the ASS expression became positive. The survival of ASS- patients receiving at least four doses at 320 IU m(-2) was significantly better than the ASS+ group at 26.5 vs 8.5 months, P=0.024.

Conclusion: ADI-PEG20 is safe and the drug is only efficacious in melanoma patients whose tumour has negative ASS expression. Argininosuccinate synthetase tumour positivity is associated with drug resistance and tumour progression.

Conflict of interest statement

Wes Sisson and John Bomalaski are employees of Polaris. The remaining authors declare no conflict of interest.

References

    1. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, Holtsberg FW, Bomalaski JS, Clark MA, Savaraj N, Feun LG, Logan TF (2005) Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 23: 7660–7668
    1. Bowles TL, Kim R, Galante J, Parsons CM, Virudachalam S, Kung HJ, Bold RJ (2008) Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 123: 1950–1955
    1. Curley SA, Bomalaski JS, Ensor CM, Holtsberg FW, Clark MA (2003) Regression of hepatocellular cancer in a patient treated with arginine deiminase. Hepatogastroenterology 50: 1214–1216
    1. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA (2004) Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 100: 826–833
    1. Dinh V, You M, Savaraj N, Wu C, Kuo M, Wangpaichitr M, Feun L (2011) Determining argininosuccinate synthetase (ASS) expression in patients with melanoma treated with arginine depleting therapy. Proc Am Soc Clin Oncol 29: 661s (abstract no. 10627)
    1. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA (2002) Pegylated arginine deiminase (ADI-SS PEG20 000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 62: 5443–5450
    1. Feun L, Wu C, Clark M, Bomalask J, Holtsberg F, Wangpaichitr M, Robles C, Savaraj N (2004) Mechanism of antitumor effect of arginine deiminase-polyethylene (ADI-PEG20) and the possible mechanism of resistance in melanoma. Proc Am Assoc Can Res 45: 1054
    1. Feun L, You M, Wu C, Wangpaichitr M, Kuo M, Savaraj N (2008a) Clinical and pharmacologic study of ADI-PEG in hepatocellular carcinoma. Proc Am Soc Clin Oncol 26: 15584
    1. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N (2008b) Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des 14: 1049–1057
    1. Holtsberg FW, Ensor CM, Steiner MR, Bomalaski JS, Clark MA (2002) Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release 80: 259–271
    1. Husson A, Brasse-Lagnel C, Fairand A, Renouf S, Lavoinne A (2003) Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem 270: 1887–1899
    1. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Ng C, Curley SA (2004) Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 22: 1815–1822
    1. Kim JH, Yu YS, Kim DH, Min BH, Kim KW (2007) Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma. Oncol Rep 18: 1373–1377
    1. Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, Gandour-Edwards R, Chuang FY, Bold RJ, Kung HJ (2009) Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 69: 700–708
    1. Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman E, Venhaus R, Pan L, Old L, Pavlick AC, Wolchok JD (2009) Phase I/II study of arginine deiminase (ADI-PEG20) in patients with advanced malignant nelanoma(MM). ASCO 27: 468s
    1. Park IS, Kang SW, Shin YJ, Chae KY, Park MO, Kim MY, Wheatley DN, Min BH (2003) Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth. Br J Cancer 89: 907–914
    1. Pinheiro JP, Boos J (2004) The best way to use asparaginase in childhood acute lymphatic leukaemia—still to be defined? Br J Haematol 125: 117–127
    1. Savaraj N, Wu C, Kuo M, You M, Wangpaichitr M, Robles C, Sepector S, Feun L (2007) The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. Drug Target Insights 2: 119–128
    1. Savaraj N, You M, Wu C, Wangpaichitr M, Kuo MT, Feun LG (2010) Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med 10: 405–412
    1. Shen LJ, Lin WC, Beloussow K, Shen WC (2003) Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. Cancer Lett 191: 165–170
    1. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR, Fennell DA (2006) In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 12: 7126–7131
    1. Takaku H, Takase M, Abe S, Hayashi H, Miyazaki K (1992) In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini. Int J Cancer 51: 244–249
    1. Tapiero H, Mathe G, Couvreur P, Tew KD (2002) I. Arginine. Biomed Pharmacother 56: 439–445
    1. Tsai W-B, Aiba I, Lee S-Y, Feun L, Savaraj N, Kuo MT (2009) Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1a/Sp4. Mol Cancer Therap 8: 3223–3233
    1. Wheatley DN (2004) Controlling cancer by restricting arginine availability—arginine-catabolizing enzymes as anticancer agents. Anticancer Drugs 15: 825–833
    1. Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, Park IS, Yoon DK, Min BH (2007) Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 120: 897–905
    1. You M, Savaraj N, Wangpaichitr M, Wu C, Kuo M, Feun L (2011) TRAIL enhances cytotoxicity of arginine depletion therapy in argininosuccinate synthetase-negative melanoma cells through interuption of autophagy via activation of caspase. Proc Am Association Cancer Res 52: 979 (abstract no. 4096)
    1. You M, Savaraj N, Wangpaichitr M, Wu C, Kuo MT, Varona-Santos J, Nguyen DM, Feun L (2010) The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. Biochem Biophys Res Commun 394: 760–766

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren